$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2016 Form 10-K Financial Statement

#000114420416127993 Filed on October 13, 2016

Income Statement

Concept	2016	2015 Q2	2015
Revenue	$948.0K	$320.0K	$1.851M
YoY Change	-48.78%	52.38%	802.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.685M	$1.450M	$5.022M
YoY Change	53.03%	-25.64%	30.78%
% of Gross Profit
Research & Development	$3.156M	$760.0K	$3.495M
YoY Change	-9.7%	-228.81%	84.14%
% of Gross Profit
Depreciation & Amortization	$577.0K	$100.0K	$5.000K
YoY Change	11440.0%	11.11%	66.67%
% of Gross Profit
Operating Expenses	$10.84M	$2.210M	$8.517M
YoY Change	27.29%	62.5%	110.56%
Operating Profit	-$9.893M		-$6.666M
YoY Change	48.41%		73.59%
Interest Expense	$807.0K	$0.00	$9.000K
YoY Change	8866.67%
% of Operating Profit
Other Income/Expense, Net	-$764.0K	$10.00K	$41.00K
YoY Change	-1963.41%	0.0%	-76.44%
Pretax Income	-$10.66M	-$1.890M	-$6.625M
YoY Change	60.86%	65.79%	80.52%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$9.764M	-$1.890M	-$6.625M
YoY Change	47.38%	65.79%	80.71%
Net Earnings / Revenue	-1029.96%	-590.63%	-357.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.206M	-$248.0K	-$926.6K
COMMON SHARES
Basic Shares Outstanding		76.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016	2015 Q2	2015
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.01M	$9.490M	$9.494M
YoY Change	142.41%	164.35%	164.46%
Cash & Equivalents		$9.494M
Short-Term Investments
Other Short-Term Assets	$264.0K	$17.00K	$182.0K
YoY Change	45.05%	112.5%	51.67%
Inventory	$22.00K
Prepaid Expenses
Receivables	$606.0K	$445.0K	$445.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$23.91M	$10.12M	$10.12M
YoY Change	136.2%	158.65%	158.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.57M	$13.00K	$13.00K
YoY Change	196623.08%	116.67%	30.0%
Goodwill
YoY Change
Intangibles		$2.360M
YoY Change		-8.35%
Long-Term Investments
YoY Change
Other Assets	$28.00K
YoY Change
Total Long-Term Assets	$27.69M	$2.373M	$2.373M
YoY Change	1067.05%	-8.06%	-8.02%
TOTAL ASSETS
Total Short-Term Assets	$23.91M	$10.12M	$10.12M
Total Long-Term Assets	$27.69M	$2.373M	$2.373M
Total Assets	$51.60M	$12.49M	$12.49M
YoY Change	313.0%	92.39%	92.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.177M	$1.104M	$1.104M
YoY Change	6.61%	271.72%	268.0%
Accrued Expenses	$920.0K	$159.0K	$159.0K
YoY Change	478.62%	62.24%	59.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$170.0K
YoY Change
Total Short-Term Liabilities	$2.291M	$1.263M	$1.263M
YoY Change	81.39%	219.75%	215.75%
LONG-TERM LIABILITIES
Long-Term Debt	$25.27M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$25.27M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.291M	$1.263M	$1.263M
Total Long-Term Liabilities	$25.27M	$0.00	$0.00
Total Liabilities	$41.66M	$1.263M	$1.263M
YoY Change	3198.73%	219.75%	215.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$47.83M
YoY Change		16.08%
Common Stock		$59.08M
YoY Change		24.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.937M	$11.23M	$11.23M
YoY Change
Total Liabilities & Shareholders Equity	$51.60M	$12.49M	$12.49M
YoY Change	313.0%	92.39%	92.51%

Cashflow Statement

Concept	2016	2015 Q2	2015
OPERATING ACTIVITIES
Net Income	-$9.764M	-$1.890M	-$6.625M
YoY Change	47.38%	65.79%	80.71%
Depreciation, Depletion And Amortization	$577.0K	$100.0K	$5.000K
YoY Change	11440.0%	11.11%	66.67%
Cash From Operating Activities	-$8.072M	-$1.210M	-$4.725M
YoY Change	70.84%	75.36%	14.68%
INVESTING ACTIVITIES
Capital Expenditures	$68.00K	-$70.00K	$13.00K
YoY Change	423.08%	16.67%	225.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$68.00K	-$70.00K	-$215.0K
YoY Change	-68.37%	16.67%	-17.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.220M		$10.00M
YoY Change	-37.8%		1983.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.66M	2.700M	10.87M
YoY Change	99.36%		206.11%
NET CHANGE
Cash From Operating Activities	-8.072M	-1.210M	-4.725M
Cash From Investing Activities	-68.00K	-70.00K	-215.0K
Cash From Financing Activities	21.66M	2.700M	10.87M
Net Change In Cash	13.52M	1.420M	5.927M
YoY Change	128.18%	-289.33%	-814.1%
FREE CASH FLOW
Cash From Operating Activities	-$8.072M	-$1.210M	-$4.725M
Capital Expenditures	$68.00K	-$70.00K	$13.00K
Free Cash Flow	-$8.140M	-$1.140M	-$4.738M
YoY Change	71.8%	80.95%	14.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	484000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	182000	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9494000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23014000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	445000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	264000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	10121000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	23906000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25574000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2360000	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2092000	USD
CY2015Q2	us-gaap	Assets Assets	12494000	USD
CY2016Q2	us-gaap	Assets Assets	51600000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	159000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	920000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1104000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1177000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59006000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67468000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47827000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57591000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	11231000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	9937000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12494000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51600000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	27556000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	1263000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	24000	USD
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	28000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	948000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	1851000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3156000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3495000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5022000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7685000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
CY2016	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	21000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-6666000	USD
CY2015	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	32000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-764000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	41000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10661000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6650000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80973000	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71495000	shares
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-893000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	USD
CY2016	us-gaap	Interest Expense InterestExpense	807000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-10657000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-6625000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-6625000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-9764000	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	0	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	14107000	USD
CY2015Q2	us-gaap	Minority Interest MinorityInterest	0	USD
CY2016	us-gaap	Interest Paid InterestPaid	485000	USD
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2016	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-28000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24044000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11231000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	77000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	170000	USD
CY2015Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2291000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1263000	USD
CY2016Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	25265000	USD
CY2015Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	10841000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	8517000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-9893000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1245000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	914000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	363000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	358000	USD
CY2016	us-gaap	Depreciation Depreciation	577000	USD
CY2015	us-gaap	Depreciation Depreciation	5000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	39000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	240000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	82000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-125000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	806000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	761000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	73000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8072000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4725000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-68000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-215000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1009000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	867000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	21664000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10867000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-23000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13520000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5904000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3590000	USD
CY2016	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	129000	USD
CY2015	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	0	USD
CY2016	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	0	USD
CY2015	ibio	Unpaid Intangible Assets Included In Accrued Expenses UnpaidIntangibleAssetsIncludedInAccruedExpenses	-12000	USD
CY2016	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	122000	USD
CY2015	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6220000	USD
CY2015	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	0	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2100000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2100000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	60375000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6633324	shares
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-33000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-48000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	24000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	26000000	USD
CY2015	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2016	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	71000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	70875000	USD
CY2016	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	807000	USD
CY2015	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	0	USD
CY2016	ibio	Sub Lease Expiration Period SubLeaseExpirationPeriod	P34Y
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2100000	USD
CY2016Q2	ibio	Registration Common Stock RegistrationCommonStock	15000000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6500000	shares
CY2016Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4043000	USD
CY2016	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	1904000	shares
CY2016	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	4729324	shares
CY2016	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.53
CY2016	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	2.08
CY2015	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2016	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	22000	USD
CY2015	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	0	USD
CY2016	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	15000000	USD
CY2015	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2016	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	565000	USD
CY2015	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	34000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	27000	USD
CY2016Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	571000	USD
CY2015Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	0	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2092000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2360000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	2100000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	2100000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2100000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9764000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6625000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9523334	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2750000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12273334	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12225441	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7583357	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.64
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.31
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.31
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.31
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1848000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	993000	USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	153000	USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	623000	USD
CY2015Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	991000	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	773000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.62
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2016	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q4	dei	Entity Public Float EntityPublicFloat	3010000	USD
CY2016	dei	Trading Symbol TradingSymbol	IBIO
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89109410	shares
CY2016Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	122000	USD
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	200000	USD
CY2016Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2015Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89109410	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89109410	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77205410	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77205410	shares
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-260000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2299000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-9000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-377000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-12000	USD
CY2016	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-270000	USD
CY2015	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-2688000	USD
CY2016	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	270000	USD
CY2015	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	2688000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17172000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14213000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	726000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3992000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1097000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	890000	USD
CY2016Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	219000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	188000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	17000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	16000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19193000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18923000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.03	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.41	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	44700000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	33500000	USD
CY2008Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5500000	USD
CY2016	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	1036000	USD
CY2015	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	995000	USD
CY2016	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	565000	USD
CY2015	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
CY2016	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	807000	USD
CY2015	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6099000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6220000	USD
CY2016	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	15000000	USD
CY2015	ibio	Stock Issued During Period Value Capital Contribution And Commitment Fee StockIssuedDuringPeriodValueCapitalContributionAndCommitmentFee	1000	USD
CY2015	ibio	Common Stock Issued For Warrant Exercises Value CommonStockIssuedForWarrantExercisesValue	867000	USD
CY2016	ibio	Common Stock Issued For Warrant Exercises Value CommonStockIssuedForWarrantExercisesValue	1009000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	914000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1245000	USD
CY2016Q2	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	1875000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8483334	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1740000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	700000	shares
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	800000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1100000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.25
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.88
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.75
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	179000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0183	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0213	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.013	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.023	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0949	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1217	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.967	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.139	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription	Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million.
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8769911	shares
CY2015	ibio	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	1711000	shares
CY2015	ibio	Class Of Warrants Or Rights Expired ClassOfWarrantsOrRightsExpired	425587	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
CY2015	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.51
CY2015	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0.66
CY2016Q2	ibio	Class Of Warrants Or Right Exercisable ClassOfWarrantsOrRightExercisable	0	shares
CY2016Q2	ibio	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable	0
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	345000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	327000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	297000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	265000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	244000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	614000	USD
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26691	shares
CY2016	ibio	Capital Lease Obligation Description CapitalLeaseObligationDescription	The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments.In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $27,000 in 2016.
CY2016Q2	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	200000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.43
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>1.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Nature of Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBioDefense Biologics LLC (“iBioDefense”) iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio Peptide Therapeutics LLC (“iBio Peptide”) iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 8) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio Manufacturing LLC (“iBio Manufacturing”) iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio CMO LLC (“iBio CMO”) iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font> square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease for the facility as well as certain equipment (see Note 10). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	65000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1265000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	914000	USD
CY2016Q2	us-gaap	Deferred Tax Asset Parents Basis In Discontinued Operation DeferredTaxAssetParentsBasisInDiscontinuedOperation	145000	USD
CY2015Q2	us-gaap	Deferred Tax Asset Parents Basis In Discontinued Operation DeferredTaxAssetParentsBasisInDiscontinuedOperation	0	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.07	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2016	ibio	Effective Income Tax Rate Reconciliationexpiration Of Stock Options And Warrants Percent EffectiveIncomeTaxRateReconciliationexpirationOfStockOptionsAndWarrantsPercent	-0.31	pure
CY2015	ibio	Effective Income Tax Rate Reconciliationexpiration Of Stock Options And Warrants Percent EffectiveIncomeTaxRateReconciliationexpirationOfStockOptionsAndWarrantsPercent	0	pure
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	89000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	255000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	0	USD
CY2016	us-gaap	Interest And Other Income InterestAndOtherIncome	43000	USD
CY2015	us-gaap	Interest And Other Income InterestAndOtherIncome	41000	USD

Files In Submission

Name	View Source	Status
0001144204-16-127993-index-headers.html	Edgar Link	pending
0001144204-16-127993-index.html	Edgar Link	pending
0001144204-16-127993.txt	Edgar Link	pending
0001144204-16-127993-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20160630.xml	Edgar Link	completed
ibio-20160630.xsd	Edgar Link	pending
ibio-20160630_cal.xml	Edgar Link	unprocessable
ibio-20160630_def.xml	Edgar Link	unprocessable
ibio-20160630_lab.xml	Edgar Link	unprocessable
ibio-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg6.jpg	Edgar Link	pending
v449304_10k.htm	Edgar Link	pending
v449304_ex21.htm	Edgar Link	pending
v449304_ex23-1.htm	Edgar Link	pending
v449304_ex31-1.htm	Edgar Link	pending
v449304_ex31-2.htm	Edgar Link	pending
v449304_ex32-1.htm	Edgar Link	pending
v449304_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2016 Form 10-K Financial Statement

#000114420416127993 Filed on October 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2016 Form 10-K Financial Statement

#000114420416127993 Filed on October 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio